Roche’s PD-L1 Phase III Breast Study Will Have Broad Enrollment Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator for Roche’s MPDL3280A in triple negative breast cancer finds it hard to differentiate members of the PD-1/PD-L1 family.